Background. There are limited randomized controlled trials of oral vitamin D supplementation in psoriasis, especially in Asia, and\nthe results are inconclusive. Objective. To investigate the clinical effect of oral vitamin D supplementation on psoriasis. Methods.\nPatients with psoriasis were randomized to receive vitamin D2 60,000 IU or similar-looking placebo pills once every 2 weeks\nfor 6 months. The primary outcome was improvement of the Psoriasis Area and Severity Index (PASI) score at 3 and 6 months\nafter treatment. Serum levels of 25(OH)D, calcium, phosphate, parathyroid hormone, and C-reactive protein and adverse events\nwere monitored. The chi-square test, Fisherâ??s exact test, Studentâ??s t-test, and Spearmanâ??s correlation analysis were used in statistical\nanalysis. Results. Of 50 subjects screened, 45 were eligible and randomized to the oral vitamin D2 group (n=23) or placebo group\n(n=22). At enrollment, themean PASI score was 4.45, and 26.7% of patients had vitamin D deficiency.At 3months, the oral vitamin\nD2 group had significantly higher PASI improvement than the placebo group (mean PASI improvement: 1.43 versus [vs.] -0.33,\np-value=0.034; mean %PASI improvement: 34.21% vs. -1.85%, p-value=0.039). The mean serum 25(OH)D level was significantly\nhigher in the oral vitamin D group than in the placebo group (27.4 vs. 22.4 ng/mL, p-value=0.029). Serum25(OH)D concentrations\nwere significantly inversely correlated with PASI scores at the 6-month follow-up. No major adverse event was observed overall.\nConclusion. Oral vitamin D2 supplementation in patients with psoriasis increased the serum vitamin D level and significantly\nimproved the treatment outcome without increasing adverse events. Trial Registration. This trial is registered with Thai Clinical\nTrials Registry TCTR20180613001.
Loading....